EHT
MCID: HYP595
MIFTS: 78

Hypertension, Essential (EHT)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Hypertension, Essential

MalaCards integrated aliases for Hypertension, Essential:

Name: Hypertension, Essential 57 13 40
Essential Hypertension 12 76 75 29 55 6 44 15 73
Hypertension 57 38 76 29 6 3
Hypertension, Salt-Sensitive Essential, Susceptibility to 57 6
Hypertension, Essential, Susceptibility to 57 6
Eht 57 75
Hypertension, Essential, Susceptibility to, 1 57
Hypertension, Essential, Susceptibility to, 2 57
Hypertension, Essential, Susceptibility to, 3 57
Hypertension, Essential, Susceptibility to, 4 57
Hypertension, Essential, Susceptibility to, 5 57
Hypertension, Essential, Susceptibility to, 6 57
Hypertension, Essential, Salt-Sensitive 57
Hypertension, Salt-Sensitive Essential 57
Hypertension, Susceptibility to 57
Hypertension, Essential 1 57
Hypertension, Essential 2 57
Hypertension, Essential 3 57
Hypertension, Essential 4 57
Hypertension, Essential 5 57
Hypertension, Essential 6 57
Idiopathic Hypertension 12
Primary Hypertension 12
Hypertensive Disease 73

Characteristics:

OMIM:

57
Inheritance:
multifactorial

Miscellaneous:
multiple genes influence susceptibility to hypertension. candidate genes include angiotensinogen (agt, ), angiotensin receptor-1 (agtr1, ), and beta-3 subunit of guanine nucleotide-binding protein (gnb3, ). susceptibility loci include hyt1 and hyt2 .


HPO:

32
hypertension, essential:
Inheritance multifactorial inheritance


Classifications:



External Ids:

OMIM 57 145500
Disease Ontology 12 DOID:10825
ICD10 33 I10
ICD9CM 35 401 401.9
NCIt 50 C3478
SNOMED-CT 68 59621000
MedGen 42 C0085580

Summaries for Hypertension, Essential

OMIM : 57 The Pickering school held that blood pressure has a continuous distribution, that multiple genes and multiple environmental factors determine the level of one's blood pressure just as the determination of stature and intelligence is multifactorial, and that 'essential hypertension' is merely the upper end of the distribution (Pickering, 1978). In this view the person with essential hypertension is one who happens to inherit an aggregate of genes determining hypertension (and also is exposed to exogenous factors that favor hypertension). The Platt school took the view that essential hypertension is a simple mendelian dominant trait (Platt, 1963). McDonough et al. (1964) defended the monogenic idea. See McKusick (1960) and Kurtz and Spence (1993) for reviews. Swales (1985) reviewed the Platt-Pickering controversy as an 'episode in recent medical history.' The Pickering point of view appears to be more consistent with the observations. (145500)

MalaCards based summary : Hypertension, Essential, also known as essential hypertension, is related to pre-eclampsia and pediatric hypertension, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Hypertension, Essential is PTGIS (Prostaglandin I2 Synthase), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and Corticotropin-releasing hormone signaling pathway. The drugs Adcirca and Adempas have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and kidney, and related phenotypes are elevated systolic blood pressure and elevated diastolic blood pressure

Disease Ontology : 12 A hypertension with no known cause. It is the most common type of hypertension.

CDC : 3 High blood pressure is a common and dangerous condition. Having high blood pressure means the pressure of the blood in your blood vessels is higher than it should be. But you can take steps to control your blood pressure and lower your risk of heart disease and stroke. About 1 of 3 U.S. adults—or about 75 million people—have high blood pressure.1Only about half (54%) of these people have their high blood pressure under control.1Many youth are also being diagnosed with high blood pressure.2 This common condition increases the risk for heart disease and stroke, two of the leading causes of death for Americans.3 Get more quick facts about high blood pressure, or learn more about high blood pressure in the United States.

UniProtKB/Swiss-Prot : 75 Essential hypertension: A condition in which blood pressure is consistently higher than normal with no identifiable cause.

Wikipedia : 76 Essential hypertension (also called primary hypertension or idiopathic hypertension) is the form of... more...

Related Diseases for Hypertension, Essential

Diseases in the Familial Hypertension family:

Hypertension, Essential Hypertension, Essential 1
Hypertension, Essential 2 Hypertension, Essential 3
Hypertension, Essential 4 Hypertension, Essential 5
Hypertension, Essential 6 Hypertension, Essential 7
Hypertension, Essential 8 Malignant Essential Hypertension
Malignant Hypertension Benign Essential Hypertension
Benign Secondary Hypertension Malignant Secondary Hypertension

Diseases related to Hypertension, Essential via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1789)
# Related Disease Score Top Affiliating Genes
1 pre-eclampsia 33.7 NOS3 NOS2 AGTR1 AGT
2 pediatric hypertension 33.6 AGT ADD1
3 diabetes mellitus, noninsulin-dependent 33.2 NOS3 GNB3 GAS5 CDKN2B-AS1 AGTR1 AGT
4 congenital hepatic fibrosis 32.1 PKD1 AGTR1
5 diabetes mellitus 31.5 NOS3 MIR155 MEN1 CDKN2B-AS1 AGTR1 AGT
6 kidney disease 31.3 PKD2 PKD1 NOS3 COL4A5 AGTR1 AGT
7 aortic coarctation 31.2 NOS3 GNB3 AGTR1 AGT
8 chronic kidney failure 31.1 PKD2 PKD1 NOS3 COL4A5 AGTR1 AGT
9 myocardial infarction 31.1 PTGIS NOS3 GNB3 CDKN2B-AS1 AGTR1 AGT
10 arteries, anomalies of 31.1 NOS3 AGTR1 AGT
11 coronary heart disease 1 30.9 NOS3 MIR155 GAS5 CDKN2B-AS1 AGTR1
12 diastolic heart failure 30.8 NOS3 AGTR1 AGT
13 end stage renal failure 30.8 PKD1 COL4A5 AGTR1 AGT
14 autosomal dominant polycystic kidney disease 30.8 PKD2 PKD1 NOS3 AGT ADD1
15 mitral valve disease 30.6 NOS3 AGTR1 AGT
16 stroke, ischemic 30.6 PTGIS NOS3 CDKN2B-AS1 AGTR1
17 renal artery disease 30.5 NOS3 AGTR1 AGT
18 ischemic optic neuropathy 30.3 NOS3 AGTR1 AGT
19 multicystic dysplastic kidney 30.3 PKD2 PKD1
20 atherosclerosis susceptibility 30.3 PTGIS NOS3 CDKN2B-AS1
21 intracranial aneurysm 30.2 PKD1 NOS3 CDKN2B-AS1
22 orthostatic intolerance 30.0 NOS3 NOS2 ECE1 AGTR1
23 platelet membrane fluidity 29.9 NOS3 NOS2
24 meningococcal infection 29.6 AGTR1 AGT ADD1
25 portal hypertension 12.6
26 renovascular hypertension 12.5
27 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 12.5
28 hypertensive heart disease 12.5
29 hypertension and brachydactyly syndrome 12.4
30 intracranial hypertension, idiopathic 12.4
31 renal hypertension 12.4
32 hypertensive encephalopathy 12.4
33 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 12.4
34 ocular hypertension 12.3
35 portal hypertension, noncirrhotic 12.3
36 hypertensive retinopathy 12.3
37 hypertension, essential 3 12.3
38 hypertension, essential 4 12.3
39 hypertension, essential 5 12.3
40 hypertension, essential 6 12.3
41 renal failure, progressive, with hypertension 12.3
42 hypertension, essential 1 12.3
43 hypertension, essential 2 12.3
44 hypertension, essential 7 12.3
45 hypertension, essential 8 12.3
46 pulmonary hypertension, primary, 4 12.2
47 heritable pulmonary arterial hypertension 12.2
48 intracranial hypertension 12.2
49 pulmonary hypertension, primary, 2 12.2
50 pulmonary hypertension, primary, 3 12.2

Comorbidity relations with Hypertension, Essential via Phenotypic Disease Network (PDN): (show top 50) (show all 300)


Abducens Nerve Disease Acquired Polycythemia
Active Peptic Ulcer Disease Acute Closed-Angle Glaucoma
Acute Conjunctivitis Acute Cystitis
Acute Ethmoiditis Acute Kidney Failure
Acute Maxillary Sinusitis Acute Myocardial Infarction
Acute Pancreatitis Acute Stress Disorder
Acute Vascular Insufficiency of Intestine Adjustment Disorder
Adrenal Gland Disease Age-Related Hearing Loss
Alcohol Abuse Allergic Rhinitis
Allergic Urticaria Alopecia, Neurologic Defects, and Endocrinopathy Syndrome
Angina Pectoris Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Asthma
Atrioventricular Block Atrophic Gastritis
Atypical Depressive Disorder Auditory System Disease
Autonomic Nervous System Disease Basilar Artery Insufficiency
Bipolar Disorder Bleeding Disorder, Platelet-Type, 11
Blepharitis Borderline Glaucoma
Borderline Personality Disorder Brain Cancer
Brain Compression Brain Edema
Brain Small Vessel Disease with or Without Ocular Anomalies Branch Retinal Artery Occlusion
Bronchitis Buerger Disease
Campylobacteriosis Cardiac Arrest
Cardiac Arrhythmia Central Nervous System Origin Vertigo
Central Retinal Artery Occlusion Central Retinal Vein Occlusion

Graphical network of the top 20 diseases related to Hypertension, Essential:



Diseases related to Hypertension, Essential

Symptoms & Phenotypes for Hypertension, Essential

Symptoms via clinical synopsis from OMIM:

57
Cardiovascular Vascular:
elevated systolic blood pressure
elevated diastolic blood pressure
elevated mean arterial pressure


Clinical features from OMIM:

145500

Human phenotypes related to Hypertension, Essential:

32
# Description HPO Frequency HPO Source Accession
1 elevated systolic blood pressure 32 HP:0004421
2 elevated diastolic blood pressure 32 HP:0005117
3 elevated mean arterial pressure 32 HP:0004972

UMLS symptoms related to Hypertension, Essential:


tremor, angina pectoris, edema, chest pain, equilibration disorder

MGI Mouse Phenotypes related to Hypertension, Essential:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.15 AGT AGTR1 ATP1B1 COL4A5 ECE1 INF2
2 homeostasis/metabolism MP:0005376 10.13 ADD1 AGT AGTR1 ATP1B1 COL4A5 ECE1
3 mortality/aging MP:0010768 10.07 ADD1 AGT AGTR1 ATP1B1 COL4A5 DARS2
4 adipose tissue MP:0005375 9.88 AGT AGTR1 COL4A5 NOS2 NOS3 PKD1
5 muscle MP:0005369 9.7 AGT ATP1B1 ECE1 MEN1 NOS2 NOS3
6 nervous system MP:0003631 9.65 ADD1 AGT AGTR1 ECE1 F12 GNB3
7 renal/urinary system MP:0005367 9.23 AGT AGTR1 COL4A5 NOS2 NOS3 PKD1

Drugs & Therapeutics for Hypertension, Essential

FDA approved drugs:

(show all 6)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Adcirca 18 TADALAFIL Eli Lilly May 2009
2
Adempas 18 RIOCIGUAT Bayer Healthcare Pharmaceuticals October 2013
3
Covera-HS 18 VERAPAMIL HYDROCHLORIDE GD Searle, Alza January 1996
4
Letairis 18 AMBRISENTAN Gilead June 2007
5
Opsumit 18 MACITENTAN Actelion Pharmaceuticals October 2013
6
Remodulin 18 TREPROSTINIL United Therapeutics May 2002

Drugs for Hypertension, Essential (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 277)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
2
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 37350-58-6, 51384-51-1 4171
3
Candesartan cilexetil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 145040-37-5 2540
4
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
5
Nifedipine Approved Phase 4,Phase 2,Phase 3,Phase 1 21829-25-4 4485
6
Bisoprolol Approved Phase 4 66722-44-9 2405
7
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 144701-48-4 65999
8
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
9
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 88150-42-9 2162
10
Amiloride Approved Phase 4,Not Applicable 2016-88-8, 2609-46-3 16231
11
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 138402-11-6 3749
12
Felodipine Approved, Investigational Phase 4,Phase 3,Not Applicable 72509-76-3 3333
13
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-93-5 3639
14
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75847-73-3 5362032 40466924
15
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76420-72-9 6917719
16
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2 137862-53-4 60846
17
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1 114798-26-4 3961
18
Nitric Oxide Approved Phase 4,Phase 2,Phase 1,Not Applicable 10102-43-9 145068
19
Metformin Approved Phase 4,Not Applicable 657-24-9 14219 4091
20
Olmesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 144689-63-4, 144689-24-7 158781 130881
21
Doxazosin Approved Phase 4,Phase 2,Phase 3 74191-85-8 3157
22
leucovorin Approved Phase 4,Phase 2,Phase 3 58-05-9 6006 143
23
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 72956-09-3 2585
24
Spironolactone Approved Phase 4,Phase 3,Phase 2,Not Applicable 52-01-7, 1952-01-7 5833
25
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
26 tannic acid Approved Phase 4,Phase 3,Not Applicable
27
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 98-92-0 936
28
Eprosartan Approved Phase 4,Phase 3 133040-01-4 5281037
29
Lercanidipine Approved, Investigational Phase 4,Phase 3,Phase 2 100427-26-7 65866
30
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
31 Lacidipine Approved, Investigational Phase 4,Phase 3 103890-78-4
32
Aspirin Approved, Vet_approved Phase 4,Early Phase 1 50-78-2 2244
33
Nebivolol Approved, Investigational Phase 4,Phase 3,Phase 2 99200-09-6, 152520-56-4, 118457-14-0 71301
34 Tomato Approved Phase 4
35
Chlorthalidone Approved Phase 4,Phase 3 77-36-1 2732
36
Allopurinol Approved Phase 4,Phase 2 315-30-0 2094
37
Eplerenone Approved Phase 4,Phase 3,Phase 2,Not Applicable 107724-20-9 443872 150310
38
Lisinopril Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83915-83-7, 76547-98-3 5362119
39
Hydralazine Approved Phase 4 86-54-4 3637
40 Manidipine Approved, Investigational Phase 4 89226-50-6
41
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
42
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
43
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
44
Indapamide Approved Phase 4,Phase 3,Not Applicable 26807-65-8 3702
45
Spirapril Approved Phase 4 83647-97-6 5311447
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
47
Serine Approved, Nutraceutical Phase 4,Not Applicable 56-45-1 5951
48
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 59-67-6 938
49
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
50 Arotinolol Investigational Phase 4 68377-92-4

Interventional clinical trials:

(show top 50) (show all 575)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension Unknown status NCT00366119 Phase 4 Ramipril
2 Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate Unknown status NCT02612298 Phase 4 Arotinolol Hydrochloride;Metoprolol succinate sustained-release tablet
3 GRK4 Polymorphisms Blood Pressure Response to Candesartan Unknown status NCT01629225 Phase 4 Candesartan
4 A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
5 BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study) Unknown status NCT02398929 Phase 4 Bisoprolol 2.5 mg;Placebo
6 Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension Unknown status NCT02641821 Phase 4 Nifedipine GITS
7 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
8 Combined Antihypertensive Therapy and Sexual Dysfunction Unknown status NCT01238705 Phase 4 Felodipine add Irbesartan;Felodipine add Metoprolol
9 Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure Unknown status NCT02357615 Phase 4 nifedipine CR tablets (Xin Ran);Adalat
10 Treatment of HYpertension: Morning Versus Evening Unknown status NCT02214498 Phase 4 Enalapril/hydrochlorothiazide;Placebo
11 Home Blood Pressure in Hypertension Management Unknown status NCT00841308 Phase 4
12 Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients Unknown status NCT00716950 Phase 4 valsartan/amlodpine;losartan/amlodpine
13 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
14 Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension Unknown status NCT00994617 Phase 4 Losartan and hydrochlorothiazide;Hydrochlorothiazide switched over with Losartan at 8 weeks
15 L-arginine Treatment in Mild Hypertension Unknown status NCT02894723 Phase 4
16 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
17 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
18 Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension Completed NCT01131546 Phase 4 Levamlodipine besylate;Amlodipine maleate
19 Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension Completed NCT02031861 Phase 4 nifedipine CR tablets (Xin Ran);nifedipine CR tablets (Adalat)
20 Canrenone as Add-on in Patients With Essential Hypertension Completed NCT02687178 Phase 4 Canrenone 50 vs canrenone 100 mg
21 The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension Completed NCT00438945 Phase 4 Eprosartan
22 A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R Completed NCT02079805 Phase 4 Azilsartan;Telmisartan
23 Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia Completed NCT02517866 Phase 4 Azilsartan Medoxomil
24 Intensive Vasodilator Therapy in Patients With Essential Hypertension Completed NCT01180413 Phase 4 Amlodipine;Ramipril;Lercanidipine;Losartan
25 Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension Completed NCT01762436 Phase 4 bisoprolol;atenolol
26 Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension Completed NCT00890591 Phase 4 olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
27 Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea Completed NCT00328965 Phase 4 Lacidipine
28 Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension. Completed NCT00654875 Phase 4 Aliskiren;Placebo to Aliskiren
29 A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension Completed NCT03276598 Phase 4 Amlodipine;Bisoprolol;Hydrochlorothiazide;Losartan;Placebo
30 Comparison of Awakening Versus Bedtime Dosing of Aspirin in Pre-Hypertension or Mild Essential Hypertension Terminated NCT00449618 Phase 4 Aspirin 100 mg;Placebo
31 The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy Completed NCT02433119 Phase 4 OROSARTAN® 5/160mg;CODIOVAN® 160/12.5mg
32 A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension Completed NCT01251146 Phase 4 Bisoprolol;Atenolol
33 A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension Completed NCT00631917 Phase 4 Aliskiren;Ramipril
34 Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension Completed NCT00130156 Phase 4 Bunazosin;Doxazosin;Valsartin
35 Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension Completed NCT00473174 Phase 4 Ramipril
36 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4 Thiazide diuretics;No diuretics
37 A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components Completed NCT00819104 Phase 4 Metoprolol XL 50mg + Amlodipine 5mg;Metoprolol XL 25 mg + Amlodipine 2.5mg;Metoprolol XL 50mg;Metoprolol XL 25 mg;Amlodipine 5mg
38 A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3) Completed NCT01431508 Phase 4 Losartan 50 mg / HCTZ 12.5 mg
39 Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension Completed NCT00861016 Phase 4 metoprolol succinate prolonged-release tablet and felodipine
40 Study of Efficacy and Safety of CVAA489 in Hypertensive Patients Completed NCT02062645 Phase 4 amlodipine/valsartan
41 Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension Completed NCT01518855 Phase 4 Nifedipine (Adalat, BAYA1040);Amlodipine (Norvasc);Diovan
42 Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension Completed NCT02242370 Phase 4 Low dose of telmisartan;High dose of telmisartan
43 Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg Completed NCT00687973 Phase 4 Valsartan/amlodipine 80/5 mg tablets;Amlodipine 5 mg capsules;Amlodipine 10 mg capsules;Atenolol 50 mg tablets;Atenolol 100 mg tablets
44 Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients Completed NCT01042392 Phase 4 Aliskiren;Ramipril;Matching placebo to Aliskiren;Matching placebo to Ramipril
45 China Stroke Primary Prevention Trial Completed NCT00794885 Phase 4 Enalapril/folic acid;Enalapril maleate
46 Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension Completed NCT00765947 Phase 4 Aliskiren;Hydrochlorothiazide;Amlodipine
47 Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314) Completed NCT00157963 Phase 4 MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks
48 PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension Completed NCT02058446 Phase 4 Amlodipine/Valsartan
49 Evaluation of Aliskiren Efficacy by Different Methods of Blood Pressure Measurements Terminated NCT01060865 Phase 4 Aliskiren
50 Hybrid Blood Pressure Monitor Validation Completed NCT01120990 Phase 4

Search NIH Clinical Center for Hypertension, Essential

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: essential hypertension

Genetic Tests for Hypertension, Essential

Genetic tests related to Hypertension, Essential:

# Genetic test Affiliating Genes
1 Essential Hypertension 29 ADD1 AGT AGTR1 ATP1B1 CYP3A5 ECE1 GNB3 NOS2 NOS3 PTGIS RGS5
2 Hypertension 29

Anatomical Context for Hypertension, Essential

MalaCards organs/tissues related to Hypertension, Essential:

41
Endothelial, Heart, Kidney, Brain, Testes, Smooth Muscle, Lung

Publications for Hypertension, Essential

Articles related to Hypertension, Essential:

(show top 50) (show all 2966)
# Title Authors Year
1
Serum Uric Acid is Independently Associated with Diastolic Dysfunction in Apparently Healthy Subjects with Essential Hypertension. ( 29278214 )
2019
2
A system view and analysis of essential hypertension. ( 29369145 )
2018
3
Analysis of Association of Angiotensin II Type 1 Receptor Gene A1166C Gene Polymorphism with Essential Hypertension. ( 29371770 )
2018
4
Effects of 12-week brisk walking training on exercise blood pressure in elderly patients with essential hypertension: a pilot study. ( 29363988 )
2018
5
Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study. ( 30406819 )
2018
6
Identification of essential hypertension biomarkers in human urine by non-targeted metabolomics based on UPLC-Q-TOF/MS. ( 30092170 )
2018
7
Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. ( 29129575 )
2018
8
Relationship between carotid artery sclerosis and blood pressure variability in essential hypertension patients. ( 29156411 )
2018
9
Association of ACE gene A2350G and I/D polymorphisms with essential hypertension in the northernmost province of China. ( 29172745 )
2018
10
E-selectin gene in essential hypertension: a case-control study. ( 29178542 )
2018
11
The evaluation of arterial stiffness of essential hypertension and white coat hypertension in children: a case-control study. ( 29223189 )
2018
12
Higher pulse pressure and risk for cardiovascular events in patients with essential hypertension: The Campania Salute Network. ( 29226693 )
2018
13
A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension. ( 29235365 )
2018
14
Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study. ( 29248384 )
2018
15
Essential Hypertension and Functional Microvascular Ageing. ( 29313304 )
2018
16
Fibroblast growth factor 23 (FGF23) gene polymorphisms are associated with essential hypertension risk and blood pressure levels in Chinese Han population. ( 29336609 )
2018
17
Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study. ( 29338113 )
2018
18
Correction to: Rakugi et al., A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension. ( 29357704 )
2018
19
Low Dose Spironolactone Monotherapy in the Management of Stage I Essential Hypertension: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial. ( 29375225 )
2018
20
Risk-Predicting Model for Incident of Essential Hypertension Based on Environmental and Genetic Factors with Support Vector Machine. ( 29380342 )
2018
21
Polymorphism of the DNA methyltransferase 1 gene is associated with the susceptibility to essential hypertension in male. ( 29400588 )
2018
22
The Impact of Vitamin D in the Treatment of Essential Hypertension. ( 29401665 )
2018
23
Sympathetic Activation in Essential Hypertension: Understanding the Toxic Trifecta. ( 29413167 )
2018
24
Associations of methylenetetrahydrofolate reductase C677T genotype with blood pressure levels in Chinese population with essential hypertension. ( 29436860 )
2018
25
Neuroprotective effect of the group III mGlu receptor agonist ACPT-I after ischemic stroke in rats with essential hypertension. ( 29438731 )
2018
26
Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension. ( 29445520 )
2018
27
Brainstem Hypoperfusion as the Inciting Factor in the Development of Essential Hypertension. ( 29462443 )
2018
28
Tianma Gouteng decoction for essential hypertension: Protocol for a systematic review and meta-analysis. ( 29465596 )
2018
29
Uric acid as an independent predictor of coronary artery disease in essential hypertension: Data from an 8-year-follow-up study. ( 29489034 )
2018
30
Changes in extracellular matrix in subcutaneous small resistance arteries of patients with essential hypertension. ( 29523048 )
2018
31
A potential risk factor of essential hypertension in case-control study: Circular RNA hsa_circ_0037911. ( 29526758 )
2018
32
Essential hypertension: the specialist as part of therapeutic intervention. ( 29535454 )
2018
33
A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension. ( 29589977 )
2018
34
Hypomethylation of the Interferon γ Gene as a Potential Risk Factor for Essential Hypertension: A Case-Control Study. ( 29643275 )
2018
35
ADRB3 Gene Trp64Arg Polymorphism and Essential Hypertension: A Meta-Analysis Including 9,555 Subjects. ( 29670643 )
2018
36
The role of autoimmune reactivity induced by heat shock protein 70 in the pathogenesis of essential hypertension. ( 29679484 )
2018
37
Familial aggregation of first degree relatives of children with essential hypertension. ( 29699426 )
2018
38
Effects of slow breathing rate on heart rate variability and arterial baroreflex sensitivity in essential hypertension. ( 29718876 )
2018
39
Plasma preptin levels are decreased in patients with essential hypertension. ( 29724293 )
2018
40
Renovascular Mistaken as Essential Hypertension due to Giant Hepatic Hydatid: A Rare Treatable Entity. ( 29731770 )
2018
41
Sonographic evaluation of renal parameters in individuals with essential hypertension and correlation with normotensives. ( 29735857 )
2018
42
Efficacy and Safety of Acupuncture for Essential Hypertension: A Meta-Analysis. ( 29735972 )
2018
43
Changes of Blood Pressure and Hemodynamic Parameters after Oral Magnesium Supplementation in Patients with Essential Hypertension-An Intervention Study. ( 29738504 )
2018
44
mRNA expression profile in peripheral blood mononuclear cells based on ADRB1 Ser49Gly and Arg389Gly polymorphisms in essential hypertension - a case-control pilot investigation in South Indian population. ( 29750638 )
2018
45
Unexpected role of the human cytomegalovirus contribute to essential hypertension in the Kazakh Chinese population of Xinjiang. ( 29752343 )
2018
46
ARG1 Gene Polymorphisms and Their Association in Individuals with Essential Hypertension: A Case-Control Study. ( 29756997 )
2018
47
Genetic predisposition for essential hypertension, based on studies of genetic polymorphisms in modern global human populations: The perspective of evolutionary biology. ( 29866388 )
2018
48
Therapeutic Effect of Ilex hainanensis Merr. Extract on Essential Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( 29867454 )
2018
49
Relationship between obstructive sleep apnoea syndrome and essential hypertension: a dose-response meta-analysis. ( 29880142 )
2018
50
Association of mitofusin 2 methylation and essential hypertension: a case-control study in a Chinese population. ( 29880838 )
2018